Irrespective of what we call them, target safety reports form a key part of risk assessment and risk mitigation plans in drug discovery and development. Why is that? Well, target-related toxicity accounts for >50% of all drug project failures (Cook et al., 2014) so it’s vital to understand the potential unintended consequences of target modulation. [...]
Abstract: How can small-to-medium pharma and biotech companies enhance the chances of running a successful drug project and maximise the return on a limited number of assets? Having a full appreciation of the safety risks associated with proposed drug targets is a crucial element in understanding the unwanted side-effects that might stop a project in [...]
ApconiX is delighted to welcome Dr Jane Barber who joins us from AstraZeneca. Jane, a dedicated drug discovery research scientist will work with the team of experts in nonclinical safety toxicology at ApconiX. Jane graduated from the University of Keele with a degree in Biology and Classical studies. After researching Molecular Parasitology and Vector Biology, [...]
Did you know that safety issues remain one of the main reason why drug projects fail? Multiple publications over recent years have continued to highlight non-clinical safety/toxicity as the most frequent reason for project failure in drug development. For example, in a study of 605 projects from GSK, AstraZeneca, Ely Lilly and Pfizer, nonclinical toxicology [...]
This poster, presented at the Gordon Research Conference in August 2017, concluded that: Target safety assessments: Provide expert assessment and interpretation of literature and available databases and are invaluable in identifying and avoiding target-related risks Inform target selection and/or prioritisation early in discovery Should contain the level of detail appropriate to the project stage Should [...]
Target Safety Assessment: Strategies and Resources, Chapter 12 of Drug Safety Evaluation Methods in Molecular Biology (vol 1641), was written by Dr Richard J Brennan, a Scientific Advisor at Sanofi in the United States. The chapter presents a summary of the information types and sources that should be investigated, and approaches that can be taken [...]
